Breaking News Instant updates and real-time market news.

HAE

Haemonetics

$34.77

-1.35 (-3.74%)

10:33
10/14/16
10/14
10:33
10/14/16
10:33

Haemonetics initiated with a Sell rating at Off Wall Street

  • 07

    Nov

HAE Haemonetics
$34.77

-1.35 (-3.74%)

08/15/16
SIDC
08/15/16
DOWNGRADE
Target $39
SIDC
Neutral
Haemonetics downgraded to Neutral from Buy at Sidoti
Sidoti analyst James Sidoti downgraded Haemonetics to Neutral citing valuation with the shares near his unchanged price target of $39.
08/03/16
BRRR
08/03/16
DOWNGRADE
BRRR
Market Perform
Haemonetics downgraded to Market Perform from Outperform at Barrington
Barrington analyst Michael Petusky downgraded Haemonetics to Market Perform saying upside looks limited following the company's Q1 results. The analyst believes the stock's risk/reward no longer favors investment.
05/16/16
05/16/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. J.C. Penney (JCP) upgraded to Outperform from Neutral at Baird by analyst Mark Altschwager, who said the stock's current risk/reward profile is attractive with a credible turnaround story unfolding at the retailer. The analyst also said management's financial targets are achievable despite secular pressures impacting the industry. 2. CB&I (CBI) upgraded to Buy at Johnson Rice as the firm believes the valuation gap between the stock and those of its peers should narrow as investors gain confidence in CB&I's cash generation and declining debt levels. 3. Vornado (VNO) upgraded to Buy at Evercore ISI by analyst Steve Sakwa, who sees catalysts ahead that include cash income that is set to contribute to the P&L from Q2 thru early 2018. 4. Haemonetics (HAE) upgraded to Neutral at Goldman with analyst David Roman saying the risk/reward is more balanced with consensus numbers and management expectations "rebased." 5. Nokia (NOK) upgraded to Buy at Canaccord citing a positive long-term risk/reward. The firm sees Nokia positioned for better execution and said it will create shareholder value through restructuring and improved synergies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/16/16
GSCO
05/16/16
UPGRADE
Target $29
GSCO
Neutral
Haemonetics upgraded to Neutral from Sell at Goldman
Goldman Sachs analyst David Roman upgraded Haemonetics to Neutral saying the risk/reward is more balanced with consensus numbers and management expectations "rebased." The analyst raised his price target for the shares to $29 from $25.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.